PIOTR TADEUSZ KONIECZNY --rekin lankidetzan egindako argitalpenak (5)

2022

  1. Moxifloxacin rescues SMA phenotypes in patient-derived cells and animal model

    Cellular and Molecular Life Sciences, Vol. 79, Núm. 8

2020

  1. Drosophila SMN2 minigene reporter model identifies moxifloxacin as a candidate therapy for SMA

    FASEB Journal, Vol. 34, Núm. 2, pp. 3021-3036

2018

  1. Targeting RNA structure in SMN2 reverses spinal muscular atrophy molecular phenotypes

    Nature Communications, Vol. 9, Núm. 1

2017

  1. In silico discovery of substituted pyrido[2,3-d] pyrimidines and pentamidine-like compounds with biological activity in myotonic dystrophy models

    PLoS ONE, Vol. 12, Núm. 6

  2. Myotonic dystrophy: candidate small molecule therapeutics

    Drug Discovery Today, Vol. 22, Núm. 11, pp. 1740-1748